All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Mirdametinib Induces Significant Responses in NF1-Associated Plexiform Neurofibroma

September 3rd 2024

Mirdametinib showed a statistically significant ORR by BICR, with deep and durable tumor volume reductions in adults and children with NF1-PN.

MT-302 Under Investigation in Advanced or Metastatic Epithelial Tumors

September 3rd 2024

Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications.

New Study Evaluates Practice Patterns and Management of Patients With Dermatofibrosarcoma Protuberans

September 2nd 2024

An international team of researchers led by Fox Chase Cancer Center evaluated practice patterns and the management of dermatofibrosarcoma protuberans.

Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies

September 2nd 2024

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

Targeted Therapy, Vaccines, and Second-Generation Checkpoint Inhibitors Seek to Redefine mCRC Treatment

September 1st 2024

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.

The OncFive: Top Oncology Articles for the Week of 8/25

August 31st 2024

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma

August 31st 2024

Jennifer R. Eads, MD, explains the relevance of negative results from the ECOG-ACRIN EA2174 trial in esophageal/gastroesophageal junction adenocarcinoma.

Abemaciclib Monotherapy Elicits No Response in Advanced RCC: Where the Field is Headed From Here

August 30th 2024

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

Encorafenib/Binimetinib Combo Approved in Europe for BRAF V600E+ NSCLC

August 30th 2024

Encorafenib plus binimetinib has won approval from the European Commission for use in patients with BRAF V600E-mutated, advanced non–small lung cancer.

Is the Current Framework of Academic Oncology Failing Community Providers?

August 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Roswell Park Again Named a Top 10 New York State Employer by Forbes

August 30th 2024

Third year in a row cancer center has been ranked on this listing, based on employee surveys.

sNDA Withdrawn for Fruquitinib Plus Paclitaxel in Second-Line Gastric Cancer in China

August 30th 2024

The supplemental new drug application for fruquintinib plus paclitaxel in second-line gastric cancer in China has been voluntarily withdrawn.

NuTide:323 Study of NUC-3373 Regimen in Second-Line CRC is Discontinued

August 30th 2024

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.

Revisit Every OncLive On Air Episode From August 2024

August 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Early Data Show High Responses With Zanubrutinib Plus Venetoclax in Treatment-Naive Del17p/TP53+ CLL/SLL

August 30th 2024

Alessandra Tedeschi, MD, discusses preliminary data from arm D of the SEQUOIA trial evaluating zanubrutinib plus venetoclax in high-risk, untreated CLL/SLL.

Stepwise Approach Helps Ease the Integration of BiTEs Into Community Cancer Centers

August 29th 2024

Courtney Van Houzen, PharmD, discusses key factors to be aware of when implementing bispecific T-cell engager programs into the community setting.

TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL

August 29th 2024

Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.

RELATIVITY-048 Data Highlight Potential of Triplet ICI Regimen for Advanced Melanoma

August 29th 2024

Ankit Mangla, MD, expands on early data from the RELATIVITY-048 trial evaluating a triplet immunotherapy regimen in untreated advanced melanoma

Dr. Richard Bleicher Promoted to Chief of New Division of Breast Surgery at Fox Chase Cancer Center

August 29th 2024

Richard Bleicher, MD, FACS, Clinical Director of the Breast Service Line, has been promoted to Division Chief of Breast Surgery.

FDA Grants Orphan Drug Designation to NXP800 for ARID1a-Deficient Ovarian Cancers

August 29th 2024

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.